Voyager Acquisition Corp Warrants

VERAXA Biotech AG successfully completed its business combination with Voyager Acquisition Corp and will begin trading on NASDAQ under ticker VRXA on June 11, 2026. The company secured $27.5 million in senior secured note financing and up to $50 million in share purchase agreements to advance its pipeline of BiTAC-TCE and BiTAC-ADC cancer therapi...

VERAXA Biotech has secured $27.5 million in senior secured note financing and a $50 million share purchase agreement with Lincoln Park Capital Fund to support its business combination with Voyager Acquisition Corp. and advance its pipeline of cancer therapies. VERAXA shareholders have approved the merger and issuance of new shares, with the combi...

VERAXA Biotech and Secarna Pharmaceuticals announced a strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for treating autoimmune and chronic immune diseases, combining their unique technology platforms.

VERAXA Biotech, an emerging leader in cancer therapies, is attending the ASCO and BIO conferences to showcase its BiTAC platform and meet with potential partners and investors. The company is preparing to list on the NASDAQ later this year.

VERAXA Biotech and OmniAb have entered a co-discovery alliance to develop a novel bispecific antibody drug conjugate program targeting solid tumors. The partnership combines VERAXA's ADC technology with OmniAb's antibody discovery solutions.